Zai Lab's Lung Cancer Study for Krazati Drug Meets Primary Endpoint
Monday, 1 April 2024, 14:57
Zai Lab Reports Success in Krazati Lung Cancer Study
Zai Lab (ZLAB) has recently announced the successful completion of a confirmatory study for Bristol Myers' (BMY) lung cancer drug, Krazati. The study results have shown that the primary endpoint for the drug's regulatory approval in China has been met.
Key Highlights:
- Zai Lab (ZLAB) confirms positive outcome in lung cancer study
- Bristol Myers' (BMY) Krazati drug achieves primary endpoint
This achievement underscores the potential effectiveness of Krazati in treating lung cancer, marking a significant milestone in Zai Lab's pursuit of regulatory approval for the drug.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.